Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)

Authors: Xiuning Le, Elaine Shum, Jennifer M. Suga, Julie R. Brahmer, Christophe Dooms, Hirva Mamdani, Hovav Nechushtan, Jonathan W. Riess, Alexander Spira, John A. Barrett, Lyndah K. Dreiling, Mark Socinski

Published: 2021-07-01

DOI: 10.1158/1538-7445.am2021-ct169

Source: Full article